Navigation Links
Roche completes acquisition of ARIUS
Date:9/24/2008

- Gains access to new screening platform for antibody therapeutics

BASEL, Switzerland, Sept. 24 /PRNewswire-FirstCall/ - Roche (SWX: ROG) announced today that it has completed the acquisition of 100% of the issued and outstanding shares and warrants of ARIUS Research (TSX: ARI). On September 19th, the Ontario Superior Court, Canada, approved the Plan of Arrangement previously approved by the security holders and announced in a press release dated 23 July 2008. All other conditions of closing have been satisfied.

ARIUS is the developer of a proprietary antibody platform called FunctionFIRST(TM), which rapidly identifies and selects antibodies based on their functional ability to affect disease before progressing into clinical development. This antibody generation engine has enabled ARIUS to develop a pipeline of more than 500 antibody drug candidates. The FunctionFIRST(TM) technology platform will allow Roche to further strengthen its developmental portfolio, initially within the areas of oncology and inflammatory diseases where this new technique offers potentially broad therapeutic applications.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totalled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 80,000 people. Additional information is available on the Internet at http://www.roche.com.

All trademarks used or mentioned in this release are protected by law.


'/>"/>
SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
2. Roche Extends Tender Offer for Ventana
3. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
4. Roche Real-Time HIV Test is Faster and Less Labor-Intensive Than Competitors
5. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
6. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
7. Med Ad News Honors Roche as Company of the Year
8. MacroChem To Participate in PIPEs Conference October 18th and 19th in New York City
9. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
10. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
11. Kosan to Reacquire Epothilone Program From Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2019)... ... October 10, 2019 , ... R3 Stem Cell announces it ... is October 18-19th, 2019 in Las Vegas with spots still open. , The speaker, ... at several Ivy League universities including Cornell, Harvard and Dartmouth. He currently serves as ...
(Date:10/8/2019)... ... October 07, 2019 , ... Erchonia Corporation, the ... (“3LT®”), today announces that the U.S. Food and Drug Administration (FDA) has granted ... the temporary relief of chronic neck and shoulder pain of musculoskeletal origin. , ...
(Date:10/3/2019)... ... October 01, 2019 , ... Cheyenne is a beautiful and ... Cheyenne’s owner, owns and operates Rebel’s Run , which offers riding lessons and ... students and trail riding guests. Mimi describes her as her “go to horse.” ...
(Date:10/3/2019)... ... October 02, 2019 , ... eKare’s inSight® digital 3D imaging ... Accelerator run by the East Midlands Academic Health Science Network (EMAHSN), the innovation arm ... in NHS by providing support to develop and deploy solutions to the most pressing ...
Breaking Biology Technology:
(Date:10/17/2019)... ... October 15, 2019 , ... Modality ... made its first appearance on the Houston Business Journal’s Fast 100 list. Modality ... , With corporate headquarters in Houston, Modality Solutions is a biopharmaceutical cold chain ...
(Date:10/11/2019)... ... 11, 2019 , ... Advanced Clinical, a clinical research services ... has been appointed Therapeutic Lead for Oncology. Dr. Tyan brings a wealth of ... scientific and delivery credentials previously offered at Advanced Clinical. , Dr. Tyan has ...
(Date:10/8/2019)... , ... October 08, 2019 , ... ... announced new apps that make it easier than ever for businesses and organizations ... The new Countdown App enables organizations to count down to or count up ...
Breaking Biology News(10 mins):